RIGL
RIGEL PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$46.72
+1.63%Year over year
Reported trailing growth
- Revenue
- +3.3%
- EBITDA
- -14.0%
- EBIT
- -16.8%
- EPS
- +221.9%
- Free cash flow
- +20.7%
- Operating cash flow
- +20.6%
Forward estimates
Based on analyst estimates
- Revenue
- +25.6%
- EBITDA
- +2.2%
- EPS
- -80.2%
Three-year CAGR
- Revenue
- +34.8%
- EBITDA
- +361.4%
- EBIT
- +418.6%
- Net income
- +1999.1%
- EPS
- +1960.6%
- Free cash flow
- +143.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026